1. Home
  2. EDD vs ATYR Comparison

EDD vs ATYR Comparison

Compare EDD & ATYR Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Morgan Stanley Emerging Markets Domestic Debt Fund Inc.

EDD

Morgan Stanley Emerging Markets Domestic Debt Fund Inc.

N/A

Current Price

$5.24

Market Cap

337.7M

Sector

Finance

ML Signal

N/A

Logo aTyr Pharma Inc.

ATYR

aTyr Pharma Inc.

N/A

Current Price

$0.29

Market Cap

49.2M

Sector

Health Care

ML Signal

N/A

Company Overview

Basic Information
Metric
EDD
ATYR
Founded
2007
2005
Country
United States
United States
Employees
N/A
N/A
Industry
Finance Companies
Biotechnology: Biological Products (No Diagnostic Substances)
Sector
Finance
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
337.7M
49.2M
IPO Year
N/A
2015

Fundamental Metrics

Financial Performance
Metric
EDD
ATYR
Price
$5.24
$0.29
Analyst Decision
Buy
Analyst Count
0
9
Target Price
N/A
★ $2.86
AVG Volume (30 Days)
305.8K
★ 2.7M
Earning Date
01-01-0001
11-05-2026
Dividend Yield
★ 7.52%
N/A
EPS Growth
N/A
★ 6.98
EPS
★ N/A
N/A
Revenue
N/A
★ $190,000.00
Revenue This Year
N/A
N/A
Revenue Next Year
N/A
N/A
P/E Ratio
N/A
★ N/A
Revenue Growth
★ N/A
N/A
52 Week Low
$4.96
$0.27
52 Week High
$6.18
$1.12

Technical Indicators

Market Signals
Indicator
EDD
ATYR
Relative Strength Index (RSI) 30.47 26.30
Support Level $4.96 N/A
Resistance Level $5.66 $0.59
Average True Range (ATR) 0.14 0.03
MACD -0.05 -0.01
Stochastic Oscillator 18.57 17.58

Price Performance

Historical Comparison
EDD
ATYR

About EDD Morgan Stanley Emerging Markets Domestic Debt Fund Inc.

Morgan Stanley Emerging Markets Domestic Debt Fund Inc is a closed-end management investment company. The company's primary investment objective is to seek a high level of current income, with a secondary investment objective of long-term capital appreciation. It seeks to achieve investment objectives by investing, under normal circumstances, at least 80% of its managed assets in emerging markets domestic debt. The fund's portfolio includes sovereign, quasi-sovereign, corporate bonds in emerging markets.

About ATYR aTyr Pharma Inc.

aTyr Pharma Inc is a clinical-stage biotechnology company focused on developing therapies for fibrosis and inflammatory conditions. Its research leverages tRNA synthetase biology to identify potential therapeutic targets. The company's discovery platform uses a proprietary library of domains derived from tRNA synthetases to explore signaling pathways. Its flagship clinical candidate, efzofitimod, is a novel biologic immunomodulatory in development for the treatment of interstitial lung disease (ILD).

Share on Social Networks: